JP2017528158A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528158A5
JP2017528158A5 JP2017524110A JP2017524110A JP2017528158A5 JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5 JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017524110 A JP2017524110 A JP 2017524110A JP 2017528158 A5 JP2017528158 A5 JP 2017528158A5
Authority
JP
Japan
Prior art keywords
seq
lentiviral vector
vector
antigen receptor
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017524110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528158A (ja
JP6940406B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067090 external-priority patent/WO2016012623A1/en
Publication of JP2017528158A publication Critical patent/JP2017528158A/ja
Publication of JP2017528158A5 publication Critical patent/JP2017528158A5/ja
Priority to JP2020156063A priority Critical patent/JP7341110B2/ja
Application granted granted Critical
Publication of JP6940406B2 publication Critical patent/JP6940406B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017524110A 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター Expired - Fee Related JP6940406B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020156063A JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462028889P 2014-07-25 2014-07-25
US62/028,889 2014-07-25
US201562155811P 2015-05-01 2015-05-01
US62/155,811 2015-05-01
EP15306036 2015-06-29
EP15306036.3 2015-06-29
PCT/EP2015/067090 WO2016012623A1 (en) 2014-07-25 2015-07-24 Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156063A Division JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Publications (3)

Publication Number Publication Date
JP2017528158A JP2017528158A (ja) 2017-09-28
JP2017528158A5 true JP2017528158A5 (enExample) 2018-08-30
JP6940406B2 JP6940406B2 (ja) 2021-09-29

Family

ID=53514131

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017524110A Expired - Fee Related JP6940406B2 (ja) 2014-07-25 2015-07-24 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020156063A Active JP7341110B2 (ja) 2014-07-25 2020-09-17 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
JP2023078059A Withdrawn JP2023113656A (ja) 2014-07-25 2023-05-10 キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター

Country Status (6)

Country Link
US (2) US10752668B2 (enExample)
EP (2) EP3511413B1 (enExample)
JP (3) JP6940406B2 (enExample)
CN (2) CN107531800B (enExample)
CA (1) CA2956385A1 (enExample)
WO (1) WO2016012623A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606970UA (en) 2012-02-23 2016-10-28 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
RU2761555C2 (ru) * 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN111032850B (zh) 2017-04-27 2024-08-13 朱诺治疗学有限公司 寡聚粒子试剂及其使用方法
IL270361B2 (en) 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
US20200331975A1 (en) 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
CA3080109A1 (en) 2017-11-03 2019-05-09 Sorrento Therapeutics, Inc. Cd38-directed chimeric antigen receptor constructs
KR102812046B1 (ko) 2018-01-17 2025-05-23 아라팅가 바이오 티엔피 유전자 요법을 위한 중합체-캡슐화된 바이러스 벡터
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
US20210032661A1 (en) * 2018-04-09 2021-02-04 The Trustees Of The University Of Pennsylvania Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector
US12215337B2 (en) * 2018-04-12 2025-02-04 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
KR20220034807A (ko) * 2019-07-16 2022-03-18 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd38에 대해 특이성을 갖는 항체 및 이의 용도
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
EP4208175A4 (en) * 2020-09-01 2025-05-07 The Trustees of The University of Pennsylvania IMPROVED GENERATION OF T-CELL TRANSDUCING LENTIVIRAL VECTORS USING A COCAL ENVELOPE
EP4244240A1 (en) 2020-11-13 2023-09-20 Honing Biosciences Means and methods for regulating intracellular trafficking of secretory or cell membrane-anchored proteins of interest
IT202100011576A1 (it) * 2021-05-06 2022-11-06 Univ Degli Studi Padova Nuova sequenza promotore per terapia genica
KR20240124919A (ko) 2021-11-15 2024-08-19 떼라벡띠스 인유두종 바이러스 항원의 발현을 위한 렌티바이러스 벡터 및 이의 hpv 유발 암 치료에 대한 구현
WO2023230471A2 (en) * 2022-05-23 2023-11-30 The General Hospital Corporation Methods and compositions for immune cell crispr screens
CA3263030A1 (en) 2022-07-27 2024-02-01 Institut Pasteur Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their use in the treatment of HPV-induced cancers
US20250025168A1 (en) 2023-07-21 2025-01-23 Cilag Gmbh International Systems and subsystems for firing a surgical instrument
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2026020171A2 (en) 2024-07-19 2026-01-22 Aera Therapeutics, Inc. Chimeric antigen receptor constructs

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
ES2315612T3 (es) 1991-04-10 2009-04-01 The Scripps Research Institute Genotecas de receptores heterodimericos usando fagemidos.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
CA2344995A1 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
PT2169073E (pt) 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
US6841359B2 (en) * 2000-10-31 2005-01-11 The General Hospital Corporation Streptavidin-binding peptides and uses thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP2005507236A (ja) * 2001-04-03 2005-03-17 キュラジェン コーポレイション 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
WO2003076669A1 (es) * 2002-03-08 2003-09-18 Cueros Industrializados Del Bajio Proceso para la incorporación de particulas termoestables a cuero o piel
US20050032173A1 (en) * 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7265205B2 (en) * 2005-02-11 2007-09-04 Uti Limited Partnership Monomeric streptavidin muteins
JP2009529917A (ja) * 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
JP2010509233A (ja) 2006-11-03 2010-03-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規sEH阻害剤およびそれらの使用
EP2147683A1 (en) * 2008-07-25 2010-01-27 DKFZ Deutsches Krebsforschungszentrum Construct and method for the internalization of cargo molecules into a cell
JP2012529278A (ja) 2009-06-11 2012-11-22 アンスティテュ キュリー 標的タンパク質の細胞内トラフィッキングを調節する方法およびキット
EP3693017A1 (en) * 2010-12-14 2020-08-12 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
CN105601741A (zh) * 2011-04-15 2016-05-25 卡姆普根有限公司 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
AU2013222288A1 (en) * 2012-02-22 2014-08-14 The Trustees Of The University Of Pennsylvania Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
DK3824905T3 (da) * 2012-08-20 2025-03-17 Fred Hutchinson Cancer Center Fremgangsmåde og sammensætninger til cellulær immunterapi
US9597357B2 (en) 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
HRP20201906T1 (hr) * 2013-12-20 2021-04-02 Fred Hutchinson Cancer Research Center Označene kimerne efektorske molekule i njihovi receptori
IL257105B (en) * 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy

Similar Documents

Publication Publication Date Title
JP2017528158A5 (enExample)
JP2016505635A5 (enExample)
JP2017537622A5 (enExample)
JP6816031B2 (ja) 非標準的なcd8+t細胞応答を生成するのに有用な方法および組成物
JP2019527055A5 (enExample)
JP2020074776A5 (enExample)
JP2016512557A5 (ja) 二重特異性分子及びそれを用いた方法
JP2015505299A5 (enExample)
EP4609876A3 (en) Anti-human papillomavirus 16 e7 t cell receptors
JP2019514373A5 (enExample)
JP2011530309A5 (enExample)
JP2016501535A5 (enExample)
JP2015533841A5 (enExample)
JP2019509063A5 (enExample)
JP2015529678A5 (enExample)
JP2020517635A5 (enExample)
JP2017538401A5 (enExample)
JP2013521789A5 (enExample)
FI3872085T3 (fi) Esimuotoiset virussekvenssit ja niiden käytöt
RU2015155821A (ru) Вакцины против малярии
RU2015153250A (ru) Cd19-специфический химерный антигенный рецептор и его применения
JP2012095652A5 (enExample)
JP2019519529A5 (enExample)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2015524422A5 (enExample)